

Lupin appoints Jon Stelzmler as president of US specialty biz

26 September 2019 | News

Jon brings to Lupin over 30 years of experience in the specialty segment and will be replacing Nicholas Hart



Pharma major Lupin Limited (Lupin) has announced the appointment of Jon Stelzmler as the President of its U.S. Specialty business.

Jon brings to Lupin over 30 years of experience in the specialty segment and will be replacing Nicholas Hart. Jon has a proven track record of building high performing teams and launching 18 major brands across 14 different therapeutic areas including Women's Health, Oncology and Anti-Infectives.

Most recently, Jon was SVP & General Manager — Women's Healthcare at Bayer where he helped build and lead a billion-dollar women's health business in the U.S. Prior to Bayer, Jon spent 12 years at Pfizer Inc. in roles of increasing commercial responsibilities in Specialty areas including Institutional sales and market access. Jon spent his early career at The Upjohn Company and Pharmacia Corporation in various sales and sales leadership positions. Jon holds a Bachelor of Science in Bacteriology from North Dakota State University.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin said, "Jon's extensive experience in the pharmaceutical industry, particularly in women's health segment in the U.S., will be a great asset for Lupin as we build our specialty business, including SOLOSEC®. We are delighted to welcome Jon on board."